gastric cancer, colorectal cancer, and pancreatic cancer
Conditions
Interventions
1:the patients without acheiving complete response of CINV,combine with Arepitant when the second cycle chemotherapy
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Diagnosed as gastric cancer, colorectal cancer, and pancreatic cancer by pathology; 2) more than 18 years old; 3) ECOG=1 score; 4) The anticipatory survival time=4 mouths; 5) The first time to chemotherapy, no any other anti-tumor therapy before enrollment, chemotherapy regimens include FOLFOX, Cape OX, SOX, FOLFIRI, FOLFOXIRI,FOLFIRINOX; 6) No radiotherapy or targeted therapy plan within two cycles chemotherapy; 7) No brain metastases and bone metastases with pain uncontrol; 8) No history of chronic digestive disease,chronic nausea and vomiting (such as the history of dizziness, meniere's syndrome); 9) The baseline blood and biochemical test meet the following criteria:neutrophil absolute count (ANC) =1.5×10^9/L; platelet =80 × 10^9/L, hemoglobin =80g/L; serum creatinine <1.5 times the normal upper limit; serum total bilirubin <2.5 times the normal upper limit;ALT,AST, ALP = 2.5 times the normal upper limit; if with the liver metastases,the value must less than 5 times the normal upper limit; 10) Childbearing age women without pregnancy, must take enough contraceptive measures during the reasearch; 11) volunteer to participate in this study.
Exclusion criteria
Exclusion criteria: 1) Allergy to Arepitant and dexamethasone; 2) Had received other chemotherapy; 3) Had received other radiotherapy of the abdomen, the thorax and the pelvis; 4) uncontrolled carcinous pain or the gastrointestinal reaction of opioid medicine; 5) happened nausea or vomiting in the past three days; 6) during past 1 year with the history of active digestive tract ulcer and gastrointestinal bleeding; 7) cant read or fill out questionnaire survey independently; 8) cant take oral medicine; 9) With poor compliance, cant complete the reaserch followed the plan; 10) with a long term to use hormone (such as immune system diseases including systemic lupus erythematosus (sle) and adrenal cortex hypofunction, etc.; 11) with brain metastases; 12) pregnant or breastfeeding woman; 13) with other malignant tumors; 14) with radiotherapy during chemotharapy; 15) The reaserchers assess not conform to the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the response of chemotherapy-induced nausea and vomiting; | — |
Countries
China
Contacts
Public ContactCao Dan
West China Hospital, Sichuan University
Outcome results
None listed